Page 1

É almirall feel the science Press Release Barcelona , Spain 22nd February , 2020 Almirall's 2020 Full - Year Results Almirall delivers on latest 2020 guidance and sets growth targets for 2021 • • The company delivered on its latest guidance despite a challenging year impacted by COVID - 19 and the genericization of Aczone® : Net Sales € 807.4 MM ( -5.4 % , flat excluding the AczoneⓇ generic impact ) , Total Revenues € 814.5 MM ( -10.3 % ) , EBITDA € 238.3MM ( -21.7 % ) , all year - on - year and due to the expected generic competition to Aczone in the US and a reduction in milestones from AstraZeneca Almirall appointed Gianfranco Nazzi as the new CEO , effective May 1 , 2021. Mr. Nazzi will bring continuity to the strategy as the business prepares for important launches to support future growth prospects A continued positive outlook for key growth drivers will be boosted in 2021 by the recent launch of KlisyriⓇ ( tirbanibulin ) in the US , with the launch in Europe expected in the second half of 2021 Almirall is advancing our strong late - stage pipeline aiming to unlock significant mid - term value . Key 2021 milestones are expected to include topline phase 3 lebrikizumab data and the anticipated approval in Europe for a psoriasis cream ( calcipotriene and betamethasone dipropionate ) commercialised under the tradename WynzoraⓇ in US Introducing Core Guidance for 2021 : Core Net Sales growth of mid - single - digit and Core EBITDA of € 190- € 210 MM ( versus 2020 Core EBITDA of € 181 MM ) which equates to total EBITDA of approximately € 215- € 235 MM • Dividend proposal of € 0.19 per share will be submitted at the next Annual General Meeting May 7th Financial highlights ( € rounded million ) Variation 2020 2019 Variation ( CER¹ ) Total Revenues 814.5 908.4 ( 10.3 % ) ( 10.3 % ) Net Sales 807.4 853.1 ( 5.4 % ) ( 5.3 % ) Other Income 7.1 55.3 ( 87.2 % ) ( 87.5 % ) Gross Profit 560.1 603.9 ( 7.3 % ) ( 7.1 % ) % of sales 69.4 % 70.8 % EBITDA 238.3 304.2 ( 21.7 % ) ( 21.6 % ) Normalized Net Income 95.1 136.1 ( 30.1 % ) ( 29.9 % ) 1 CER ( Constant Exchange Rates ) : Excluding the effects of exchange rate fluctuations .